Huntington’s disease is a progressive, inherited brain disorder that affects movement, cognition and emotions. It usually appears in adulthood, often between 30 and 50 years of age, and has long lacked a cure. Recent research has renewed interest in early diagnosis, disease markers and gene-based treatment strategies.
What Huntington’s Disease Is
Huntington’s disease is caused by an expanded CAG repeat in the HTT gene. In healthy people, the repeat count remains below 35. A repeat length above 39 leads to the disease. Higher repeat counts are usually linked with earlier onset. The disorder damages nerve cells, especially in the striatum, and later affects the cortex and white matter.
Why Early Detection Matters
Researchers have found that brain and behavioural changes can begin many years before movement symptoms appear. These early changes may include:
- Subtle cognitive decline.
- Mood and behavioural changes.
- Reduced cognitive flexibility.
- Attention deficits linked to brain circuit disruption.
Such findings support the idea of a long treatment window before major disability develops.
Gene Therapy Trial Results
A recent clinical trial tested AMT-130, a gene therapy designed to reduce production of toxic mutant huntingtin protein. The treatment was given to 29 patients with confirmed Huntington’s disease. The trial showed slower cognitive decline on standard tests, especially in processing speed and reading ability. A key biomarker, neurofilament light in cerebrospinal fluid, also fell after three years, suggesting possible protection of brain cells.
Implications for Future Treatment
The new findings strengthen the case for earlier intervention in Huntington’s disease. They also show the importance of biomarkers and brain imaging in clinical trials. If further studies confirm safety and effectiveness, gene therapy may become a disease-modifying option rather than only a symptom-management approach.
Last Modified: April 27, 2026